Paraganglioma of the Head and Neck: A Review

Overview

Journal Endocr Pract

Specialty Endocrinology

Date 2022 Oct 17

PMID 36252779

Authors

Lyndsey Sandow

Rajat Thawani

Myung Sun Kim

Michael C Heinrich

Affiliations

Soon will be listed here.

Abstract

Objective: To review the epidemiology, presentation, diagnosis, and management of head and neck paragangliomas.

Methods: A literature review of english language papers with focus on most current literature.

Results: Paragangliomas (PGLs) are a group of neuroendocrine tumors that arise in the parasympathetic or sympathetic ganglia. Head and neck PGLs (HNPGLs) comprise 65% to 70% of all PGLs and account for 0.6% of all head and neck cancers. The majority of HNPGLs are benign, and 6% to 19% of all HNPGLs develop metastasis outside the tumor site and significantly compromise survival. PGLs can have a familial etiology with germline sequence variations in different susceptibility genes, with the gene encoding succinate dehydrogenase being the most common sequence variation, or they can arise from somatic sequence variations or fusion genes. Workup includes biochemical testing to rule out secretory components, although it is rare in HNPGLs. In addition, imaging modalities, such as computed tomography and magnetic resonance imaging, help in monitoring in surgical planning. Functional imaging with DOTATATE-positron emission tomography, 18F-fluorodeoxyglucose, or 18F-fluorohydroxyphenylalanine may be necessary to rule out sites of metastases. The management of HNPGLs is complex depending on pathology, location, and aggressiveness of the tumor. Treatment ranges from observation to resection to systemic treatment. Similarly, the prognosis ranges from a normal life expectancy to a 5-year survival of 11.8% in patients with distant metastasis.

Conclusion: Our review is a comprehensive summary of the incidence, mortality, pathogenesis, presentation, workup and management of HNPGLs.

Citing Articles

Identification of a pathogenic SDHD mutation in a Chinese family with hereditary head and neck paraganglioma: implications for genetic counseling and management.

Wang P, Gao L, Zhang W, Guo R, Xia Y World J Surg Oncol. 2025; 23(1):4.

PMID: 39754145 PMC: 11697643. DOI: 10.1186/s12957-024-03641-w.

[Paragangliomas of the head and neck].

Strasser V, Steinbichler T Radiologie (Heidelb). 2024; 64(12):960-970.

PMID: 39531067 DOI: 10.1007/s00117-024-01395-w.

Delayed and Long-Lasting Response to 177Lu-DOTATATE in a Head and Neck Paraganglioma: Case Report and Literature Review.

Ruffini Egea S, Campos Ramirez S, Pascual de la Fuente N, Monreal Cepero M, Mocha Campillo F, Trincado Cobos P Case Rep Oncol. 2024; 17(1):1252-1257.

PMID: 39478702 PMC: 11524611. DOI: 10.1159/000541359.

Laryngeal Paraganglioma with Neck Metastasis.

Tripuraneni S, Gera S, Patibandla A, Rangisetty A Indian J Otolaryngol Head Neck Surg. 2024; 76(5):4648-4652.

PMID: 39376327 PMC: 11455980. DOI: 10.1007/s12070-024-04734-4.

Head and Neck Paragangliomas: 16-year Single-center Experience and Mini Review on Diagnosis, Treatment, and Follow-up.

Aydemir G, Ardic F, Kara C, Bir F Medeni Med J. 2024; 39(3):192-203.

PMID: 39350541 PMC: 11572209. DOI: 10.4274/MMJ.galenos.2024.91668.

References

Janssen I, Chen C, Taieb D, Patronas N, Millo C, Adams K . 68Ga-DOTATATE PET/CT in the Localization of Head and Neck Paragangliomas Compared with Other Functional Imaging Modalities and CT/MRI. J Nucl Med. 2015; 57(2):186-91. PMC: 4738157. DOI: 10.2967/jnumed.115.161018. View

Gimm O, DeMicco C, Perren A, Giammarile F, Walz M, Brunaud L . Malignant pheochromocytomas and paragangliomas: a diagnostic challenge. Langenbecks Arch Surg. 2011; 397(2):155-77. DOI: 10.1007/s00423-011-0880-x. View

Mete O, Asa S, Gill A, Kimura N, de Krijger R, Tischler A . Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas. Endocr Pathol. 2022; 33(1):90-114. DOI: 10.1007/s12022-022-09704-6. View

Gilbo P, Morris C, Amdur R, Werning J, Dziegielewski P, Kirwan J . Radiotherapy for benign head and neck paragangliomas: a 45-year experience. Cancer. 2014; 120(23):3738-43. DOI: 10.1002/cncr.28923. View

Muracciole X, Regis J . Radiosurgery and carcinogenesis risk. Prog Neurol Surg. 2008; 21:207-213. DOI: 10.1159/000157166. View

Chouaib S, Noman M, Kosmatopoulos K, Curran M . Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer. Oncogene. 2016; 36(4):439-445. PMC: 5937267. DOI: 10.1038/onc.2016.225. View

Jimenez C, Rohren E, Habra M, Rich T, Jimenez P, Ayala-Ramirez M . Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma. Curr Oncol Rep. 2013; 15(4):356-71. DOI: 10.1007/s11912-013-0320-x. View

Janeway K, Liegl B, Harlow A, Le C, Perez-Atayde A, Kozakewich H . Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors. Cancer Res. 2007; 67(19):9084-8. DOI: 10.1158/0008-5472.CAN-07-1938. View

Janssen I, Chen C, Millo C, Ling A, Taieb D, Lin F . PET/CT comparing (68)Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2016; 43(10):1784-91. PMC: 8194362. DOI: 10.1007/s00259-016-3357-x. View

10.

Kunst H, Rutten M, de Monnink J, Hoefsloot L, Timmers H, Marres H . SDHAF2 (PGL2-SDH5) and hereditary head and neck paraganglioma. Clin Cancer Res. 2011; 17(2):247-54. DOI: 10.1158/1078-0432.CCR-10-0420. View

11.

Hollinshead K, Tennant D . Mitochondrial metabolic remodeling in response to genetic and environmental perturbations. Wiley Interdiscip Rev Syst Biol Med. 2016; 8(4):272-85. PMC: 4982039. DOI: 10.1002/wsbm.1334. View

12.

Baysal B, Ferrell R, Willett-Brozick J, Lawrence E, Myssiorek D, Bosch A . Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science. 2000; 287(5454):848-51. DOI: 10.1126/science.287.5454.848. View

13.

Persky M, Setton A, Niimi Y, Hartman J, Frank D, Berenstein A . Combined endovascular and surgical treatment of head and neck paragangliomas--a team approach. Head Neck. 2002; 24(5):423-31. DOI: 10.1002/hed.10068. View

14.

Ramsay H, Kairemo K, Jekunen A . Somatostatin receptor imaging of olfactory neuroblastoma. J Laryngol Otol. 1996; 110(12):1161-3. DOI: 10.1017/s0022215100136023. View

15.

Papaspyrou K, Mewes T, Rossmann H, Fottner C, Schneider-Raetzke B, Bartsch O . Head and neck paragangliomas: Report of 175 patients (1989-2010). Head Neck. 2011; 34(5):632-7. DOI: 10.1002/hed.21790. View

16.

Castro-Vega L, Letouze E, Burnichon N, Buffet A, Disderot P, Khalifa E . Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas. Nat Commun. 2015; 6:6044. PMC: 4354166. DOI: 10.1038/ncomms7044. View

17.

Kimura N, Shiga K, Kaneko K, Sugisawa C, Katabami T, Naruse M . The Diagnostic Dilemma of GATA3 Immunohistochemistry in Pheochromocytoma and Paraganglioma. Endocr Pathol. 2020; 31(2):95-100. DOI: 10.1007/s12022-020-09618-1. View

18.

Zang Y, Dai C, Xu X, Cai X, Wang G, Wei J . Comprehensive analysis of potential immunotherapy genomic biomarkers in 1000 Chinese patients with cancer. Cancer Med. 2019; 8(10):4699-4708. PMC: 6712454. DOI: 10.1002/cam4.2381. View

19.

Erickson D, Kudva Y, Ebersold M, Thompson G, Grant C, Van Heerden J . Benign paragangliomas: clinical presentation and treatment outcomes in 236 patients. J Clin Endocrinol Metab. 2001; 86(11):5210-6. DOI: 10.1210/jcem.86.11.8034. View

20.

de Flines J, Jansen J, Elders R, Siemers M, Vriends A, Hes F . Normal life expectancy for paraganglioma patients: a 50-year-old cohort revisited. Skull Base. 2012; 21(6):385-8. PMC: 3312129. DOI: 10.1055/s-0031-1287681. View